

THE CHARACTERISATION OF RISK FACTORS,
SUBSTRATE AND MANAGEMENT STRATEGIES
FOR
ATRIAL FIBRILLATION

Geetanjali Rangnekar

BSc (Honours)

Centre for Heart Rhythm Disorders

School of Medicine

The University of Adelaide

A thesis submitted to The University of Adelaide in fulfilment of the
requirements of the degree of

Doctor of Philosophy

August 2014

To my parents, Abhay and Suniti

To my sister and brother in law, Devyani and Harshit

In loving memory of my grandparents

TABLE OF CONTENTS

ABSTRACT.....	17
DECLARATION	19
ACKNOWLEDGEMENTS.....	20
COMMUNICATIONS TO LEARNED SOCIETIES.....	21
PRIZES AND AWARDS DURING CANDIDATURE.....	24
CHAPTER ONE.....	25
LITERATURE REVIEW.....	25
1.1 INTRODUCTION.....	25
1.1.1 <i>The Risk Factors Associated with Atrial Fibrillation</i>	26
1.1.1.1 Conventional Risk Factors Associated with Atrial Fibrillation	27
1.1.1.1.1 Advancing Age	27
1.1.1.1.2 Gender	28
1.1.1.1.3 Hypertension (HT).....	29
1.1.1.1.4 Left Ventricular Hypertrophy (LVH)	31
1.1.1.1.5 Congestive Heart Failure (CHF)	32
1.1.1.1.6 Coronary Artery Disease (CAD).....	33
1.1.1.1.7 Myocardial Infarction (MI).....	34
1.1.1.1.8 Diabetes Mellitus (DM).....	35
1.1.1.1.9 Congenital Heart Disease (CHD)	36
1.1.1.1.10 Valvular Heart Disease (VHD)	37

1.1.1.1.11	Cigarette Smoking.....	39
1.1.1.1.12	Alcohol Consumption.....	40
1.1.1.2	New Risk Factors Associated with Atrial Fibrillation	40
1.1.1.2.1	Obesity.....	41
1.1.1.2.2	Obstructive Sleep Apnoea (OSA)	42
1.1.1.2.3	Aortic Stiffness.....	43
1.1.1.2.4	Familial Atrial Fibrillation	43
1.1.1.3	Summary	44
1.2	CHARACTERIZATION OF THE SUBSTRATE ASSOCIATED WITH NEW ONSET ATRIAL FIBRILLATION	45
1.2.1	<i>Definition of New Onset Atrial Fibrillation</i>	45
1.2.2	<i>Management of New Atrial Fibrillation</i>	45
1.2.3	<i>Mechanisms of Atrial Fibrillation</i>	46
1.2.3.1	Role of Triggers in Atrial Fibrillation.....	46
1.2.3.2	Role of Substrate in Atrial Fibrillation	47
1.2.4	<i>Non Invasive Characterisation of Substrate Associated with Atrial Fibrillation</i>	49
1.2.4.1	Ambulatory Holter Monitoring	49
1.2.4.2	Electrocardiogram (ECG) Abnormalities.....	51
1.2.4.3	Echocardiographic Abnormalities	51
1.2.4.4	Cardiac Magnetic Resonance Imaging (CMR).....	53
1.2.5	<i>Summary</i>	54
1.3	CONSEQUENCES OF ATRIAL FIBRILLATION.....	55
1.3.1	<i>Economic Burden of Atrial Fibrillation</i>	55

1.3.2	<i>Hospital Burden of Atrial Fibrillation</i>	56
1.3.2.1	Trends in Elective Admissions for Atrial Fibrillation	58
1.3.2.2	Trends in Emergency Department Admissions for Atrial Fibrillation	60
1.3.3	<i>Atrial Fibrillation Rehospitalisations</i>	61
1.3.4	<i>Summary</i>	63
1.3.5	<i>Thromboembolic Risk Associated with Atrial Fibrillation</i>	64
1.3.5.1	Abnormalities in the Atrial and Vessel Wall	65
1.3.5.2	Abnormalities in the Blood Flow	66
1.3.5.3	Abnormalities in the Blood Constituents	67
1.3.6	<i>Bio-markers of Thrombogenesis in Atrial Fibrillation</i>	69
1.3.6.1	CRP and IL-6	69
1.3.6.2	Asymmetric Dimethyl Arginine (ADMA)	71
1.3.6.3	Endothelin-1 (ET-1)	73
1.3.6.4	CD40 Ligand (CD40L)	74
1.3.6.5	Cell Adhesion Molecules	75
1.3.6.6	Extracellular Matrix (ECM) Remodelling Proteins	76
1.3.6.7	Myeloperoxidase (MPO)	77
1.3.7	<i>Summary</i>	78
1.4	TERTIARY CARE MANAGEMENT STRATEGIES FOR ATRIAL FIBRILLATION	79
1.4.1	<i>Rate Control Versus Rhythm Control Trials</i>	80
1.4.2	<i>Rate Control Strategies</i>	81
1.4.3	<i>Rhythm Control Strategies</i>	83
1.4.3.1	Pharmacological Interventions	83

1.4.3.2	Non-Pharmacological Interventions.....	84
1.4.4	<i>Anticoagulation in Atrial Fibrillation.....</i>	86
1.4.5	<i>Summary.....</i>	87

**INDEPENDENT RISK FACTORS FOR THE DEVELOPMENT OF NON-
VALVULAR ATRIAL FIBRILLATION: A SYSTEMATIC LITERATURE REVIEW
AND META-ANALYSIS 89**

2.1	INTRODUCTION.....	89
2.2	METHODS	90
2.2.1	<i>Search Strategy.....</i>	90
2.2.2	<i>Risk Factors Examined.....</i>	91
2.2.3	<i>Statistical Analysis.....</i>	92
2.3	RESULTS.....	93
2.3.1	<i>Study Characteristics.....</i>	93
2.3.2	<i>Independent Predictors of Atrial Fibrillation.....</i>	93
2.3.2.1	Chronic Heart Failure (CHF).....	94
2.3.2.2	Gender	94
2.3.2.3	Coronary Artery Disease (CAD)	94
2.3.2.4	Hypertension (HT).....	95
2.3.2.5	Left Ventricular Hypertrophy (LVH).....	95
2.3.2.6	Diabetes Mellitus (DM)	95
2.3.2.7	Advancing Age.....	96
2.3.2.8	Body Mass Index (BMI)	96
2.3.2.9	Alcohol Consumption (AC)	96

2.3.2.10	Cigarette Smoking (CS).....	97
2.3.3	<i>Population Attributable Risk (PAR)</i>	97
2.5	DISCUSSION	97
2.5.1	<i>Chronic Heart Failure</i>	98
2.5.2	<i>Hypertension</i>	99
2.5.3	<i>Metabolic Syndrome (Diabetes Mellitus and Obesity)</i>	100
2.5.4	<i>Demographics (Aging and Gender)</i>	101
2.5.5	<i>Non-predictors of Atrial Fibrillation Development</i>	102
2.6	CLINICAL IMPLICATIONS	103
2.7	LIMITATIONS	103
2.8	CONCLUSIONS	104
2.9	FIGURES	106
	FIGURE 1 STUDY SEARCH CRITERIA	106
	FIGURE 2 UNIVARIATE ANALYSES RESULTS FOR ALL RISK FACTORS.	107
	FIGURE 3 MULTIVARIATE ANALYSES RESULTS FOR ALL RISK FACTORS.....	108
2.10	TABLES.....	109
	TABLE 1 STUDY CHARACTERISTICS AND BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS	109
	TABLE 2 CONGESTIVE HEART FAILURE.....	112
	TABLE 3 MALE GENDER.....	115
	TABLE 4 CORONARY ARTERY DISEASE	117
	TABLE 5 HYPERTENSION	121
	TABLE 6 LEFT VENTRICULAR HYPERTROPHY	126

TABLE 7 DIABETES MELLITUS	130
TABLE 8 AGE	135
TABLE 9 BODY MASS INDEX	139
TABLE 10 ALCOHOL CONSUMPTION	143
TABLE 11 CIGARETTE SMOKING	145
TABLE 12 WEIGHTS OF EACH STUDY IN EACH UNADJUSTED AND ADJUSTED ANALYSIS	147
TABLE 13 POPULATION ATTRIBUTABLE RISK FOR MODIFIABLE RISK FACTORS	149

CHAPTER THREE 150

CHARACTERISATION OF THE STRUCTURAL AND ELECTRICAL

REMODELLING ASSOCIATED WITH NEW ONSET ATRIAL FIBRILLATION 150

3.1 INTRODUCTION.....	150
3.2 METHODS	151
3.2.1 <i>Recruitment of Newly Diagnosed Atrial Fibrillation Patients</i>	151
3.2.2 <i>Recruitment of Age-matched Controls</i>	152
3.2.3 <i>Structured Clinical Interview</i>	153
3.2.4 <i>Structural Substrate Assessment</i>	153
3.2.5 <i>Electrical Substrate Assessment</i>	154
3.2.6 <i>Statistics</i>	155
3.3 RESULTS.....	156
3.3.1 <i>Baseline Characteristics of Controls vs AF Patients</i>	156
3.3.2 <i>Baseline Characteristics of PAF vs PerAF Patients</i>	156

3.3.3	<i>Structural Substrate Assessment</i>	157
3.3.3.1	Left Atrial Longitudinal Axis	157
3.3.3.2	Left Atrial Transverse Axis	157
3.3.3.3	Left Atrial Area	158
3.3.3.4	Left Atrial Volume	158
3.3.3.5	Left Ventricular Hypertrophy: Interventricular Septal Diameter (IVSd)	158
3.3.3.6	Left Ventricular Ejection Fraction (LVEF)	159
3.3.3.7	Mitral E Velocity	159
3.3.3.8	Mitral A Velocity	159
3.3.3.9	E/A Ratio	159
3.3.3.10	Pulmonary Vein S/D Ratio	159
3.3.3.11	Pulmonary Vein Septal E'	160
3.3.4	<i>Electrical Substrate</i>	160
3.3.4.1	Atrial Ectopy Burden and Relative Earliness	160
3.4	DISCUSSION	160
3.4.1	<i>Substrate in New Paroxysmal AF</i>	161
3.4.2	<i>Substrate in New Persistent AF</i>	162
3.5	CLINICAL IMPLICATIONS	164
3.6	LIMITATIONS	165
3.7	CONCLUSIONS	166
3.8	FIGURES	167
	FIGURE 1 RECRUITMENT OF CONTROLS AND NEW AF PATIENT	167
	FIGURE 2 LEFT ATRIAL DILATION PARAMETERS IN CONTROLS, NEW PAF AND NEW PERAF	168

FIGURE 3 LEFT VENTRICULAR MEASUREMENTS IN THE CONTROLS, NEW PAF AND NEW PERAF PATIENTS	169
FIGURE 4 LEFT VENTRICULAR DIASTOLIC FUNCTION IN CONTROLS, NEW PAF AND NEW PERAF ..	170
FIGURE 5 ATRIAL PREMATURE BEATS PER HOUR IN CONTROLS AND NEW PAF	171
3.9 TABLES.....	172
TABLE 1 BASELINE CHARACTERISTICS OF THE CONTROLS AND NEW AF GROUPS	172
CHAPTER FOUR.....	173
CHARACTERISATION OF THE INFLAMMATORY CHANGES ASSOCIATED WITH NEW ONSET ATRIAL FIBRILLATION: IMPLICATIONS FOR INCREASED THROMBOEMBOLIC RISK.....	173
4.1 INTRODUCTION.....	173
4.2 METHODS	174
4.2.1 <i>Recruitment of Newly Diagnosed Atrial Fibrillation Patients</i>	174
4.2.2 <i>Recruitment of Age-matched Controls</i>	175
4.2.3 <i>Structured Clinical Interview</i>	176
4.2.4 <i>Blood Collection</i>	176
4.2.5 <i>Bio-markers Measured</i>	177
4.2.6 <i>Enzyme-Linked Immunosorbent Assay</i>	178
4.2.7 <i>Statistical Analysis</i>	178
4.3 RESULTS.....	179
4.3.1 <i>Baseline Characteristics</i>	179

4.3.2	<i>Bio-markers of Thrombogenesis</i>	179
4.3.2.1	Endothelial Dysfunction and Vascular Function	179
4.3.2.2	Inflammatory Markers	180
4.3.2.3	Extracellular Matrix (ECM) Remodeling	180
4.4	DISCUSSION	180
4.4.1	<i>Endothelial Dysfunction and Vascular Function</i>	181
4.4.2	<i>Inflammation</i>	182
4.4.3	<i>ECM Remodeling</i>	184
4.5	CLINICAL IMPLICATIONS	185
4.6	LIMITATIONS	185
4.7	CONCLUSIONS	186
4.8	FIGURES	187
	FIGURE 1 RECRUITMENT OF CONTROLS AND NEW AF PATIENTS.....	187
	FIGURE 2 ENDOTHELIAL DYSFUNCTION AND VASCULAR FUNCTION MEASURES IN CONTROLS AND NEW AF.....	188
	FIGURE 3 MARKERS OF INFLAMMATION IN CONTROLS AND NEW AF	189
4.9	TABLES.....	191
	TABLE 1 BASELINE CHARACTERISTICS OF THE CONTROLS COMPARED TO AF PATIENTS.....	191
CHAPTER FIVE.....		192
PREDICTORS AND APPROPRIATENESS OF HOSPITALISATIONS IN PATIENTS WITH ACUTE ATRIAL FIBRILLATION.....		192
5.1	INTRODUCTION.....	192

5.2	METHODS	193
5.2.1	<i>Sample</i>	193
5.2.2	<i>Data Extraction</i>	193
5.2.3	<i>Baseline Characteristics</i>	193
5.2.4	<i>Definitions</i>	194
5.2.5	<i>Statistics</i>	195
5.3	RESULTS.....	196
5.3.1	<i>Patient Sample</i>	196
5.3.2	<i>Baseline Characteristics</i>	196
5.3.3	<i>Avoidable Hospital Admissions</i>	197
5.3.4	<i>Predictors of Index Hospitalisation</i>	197
5.4	DISCUSSION	198
5.4.1	<i>Avoidable Hospital Admissions for AF</i>	198
5.4.2	<i>Predictors of Hospital Admission</i>	200
5.5	CLINICAL IMPLICATIONS	200
5.6	LIMITATIONS	201
5.7	CONCLUSIONS	202
5.8	FIGURES	203
	FIGURE 1 EXCLUSION CRITERIA AND PATIENT SELECTION	203
	FIGURE 2 UNIVARIATE AND MULTIVARIATE PREDICTORS OF AF HOSPITALIZATION	204
5.9	TABLES.....	205

TABLE 1 BASELINE CHARACTERISTICS	205
TABLE 2 CHARACTERISTICS OF ‘LOW-RISK’ AF PATIENTS.....	207
TABLE 3 PHARMACEUTICAL AGENTS: DRUG CATEGORIES AND DRUG TYPE.....	208
CHAPTER SIX.....	209
INCIDENCE AND PREDICTORS OF REHOSPITALISATION IN PATIENTS	
PRESENTING TO HOSPITAL WITH ATRIAL FIBRILLATION.....	209
6.1 INTRODUCTION.....	209
6.2 METHODS	210
6.2.1 <i>Study Design and Sample</i>	210
6.2.2 <i>Data Abstraction</i>	210
6.2.3 <i>Medication Profile</i>	211
6.2.4 <i>Acute Presentation Characteristics and Management Strategies</i>	211
6.2.5 <i>Follow-up</i>	212
6.2.6 <i>Statistical Analysis</i>	213
6.3 RESULTS.....	214
6.3.1 <i>Patient Sample</i>	214
6.3.2 <i>Baseline Characteristics</i>	215
6.3.3 <i>Burden of Readmissions</i>	215
6.3.4 <i>Primary Reasons for Readmissions</i>	216
6.3.5 <i>Predictors of All-cause Readmissions to Hospital</i>	216
6.3.6 <i>Predictors of Atrial Fibrillation Readmissions</i>	217

6.3.7	<i>Mortality Associated with Presentation with AF</i>	217
6.4	DISCUSSION	218
6.4.1	<i>Predictors of All-cause Readmission to Hospital</i>	218
6.4.2	<i>Atrial Fibrillation Readmissions</i>	219
6.4.3	<i>Mortality</i>	220
6.5	CLINICAL IMPLICATIONS	221
6.6	LIMITATIONS	222
6.7	CONCLUSIONS	222
6.8	FIGURES	223
	FIGURE 1 EXCLUSION CRITERIA AND PATIENT SELECTION	223
	FIGURE 2 REASONS FOR READMISSIONS	224
6.9	TABLES.....	225
	TABLE 1 BASELINE CHARACTERISTICS: FULL PATIENT COHORT	225
	TABLE 2 UNIVARIATE AND MULTIVARIATE PREDICTORS OF REHOSPITALISATIONS	226
	TABLE 3 UNIVARIATE AND MULTIVARIATE PREDICTORS OF AF SPECIFIC REHOSPITALISATIONS	228
	TABLE 4: PHARMACEUTICAL AGENTS: DRUG CATEGORIES AND DRUG TYPE.....	230
	CHAPTER SEVEN	231
	FINAL DISCUSSIONS	231
	CHAPTER EIGHT	234
	FUTURE DIRECTIONS.....	234

APPENDIX 1	236
STRUCTURED INTERVIEW: AF PATIENTS.....	236
STRUCTURED INTERVIEW: COMMUNITY CONTROLS	240
APPENDIX 2	244
CONGESTIVE HEART FAILURE: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	244
MALE GENDER: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS.....	245
CORONARY ARTERY DISEASE: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS.....	246
HYPERTENSION: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	247
LEFT VENTRICULAR HYPERTROPHY: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	248
DIABETES MELLITUS: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS.....	249
AGE: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	250
BMI: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	251
ALCOHOL CONSUMPTION: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	252
CIGARETTE SMOKING: UNIVARIATE AND MULTIVARIATE STATISTICAL OUTPUTS	253
APPENDIX 3	254
EXCLUSION DUE TO MIS-CODING OF ATRIAL FIBRILLATION (148) FROM TOTAL PATIENT SAMPLE (N=858).....	254
APPENDIX 4	255
OUTPUT TABLE FOR UNIVARIATE AND MULTIVARIATE ANALYSIS OF PREDICTORS OF HOSPITAL ADMISSION.....	255
APPENDIX 5	256

ETHICS APPROVALS FOR CHAPTERS 3 & 4	256
ETHICS APPROVAL FOR CHAPTERS 5 & 6.....	257
ETHICAL ISSUES:	258
CHAPTER NINE.....	259
REFERENCES	259

Abstract

The rising global incidence and prevalence of atrial fibrillation (AF) imposes significant burden on health care systems. Recently, several novel risk factors for AF have been identified. However, there remains a need to understand the differential impact of more established predisposing factors for incident AF. Further, there is insufficient knowledge surrounding the atrial changes that occur at the advent of AF and how this arrhythmia is managed on presentation to health care facilities. This thesis seeks to improve our understanding of the risk factors associated with this arrhythmia; to characterise any detrimental changes that occur upon its onset and to identify the AF patients that are most likely to significantly burden the hospital system. To this effect, the focus of each of the chapters is presented forthwith.

Chapter 2 focuses on the independent risk factors for incident non-valvular AF via a systematic literature review and meta-analysis. This study provides the absolute and independent effect of each established risk factor on AF development and estimates the proportion of AF cases that could potentially be prevented if modifiable risk factors were targeted at the population level.

Chapters 3 and 4 characterise the entity of newly diagnosed AF. Chapter 3 determines the existence of structural and electrical remodelling that may be present at an early stage of this arrhythmias' evolution. Detrimental changes were found in the form of electrical substrate in paroxysmal new AF and structural substrate in persistent new AF. Chapter 4 examines the thrombogenic risk associated with new onset AF. This study shows the existence of elevated levels of pro-thrombotic bio-markers and

emphasises the need for appropriate anti-coagulation at this early stage of the AF disease process.

Chapters 5 and 6 focus on the burden that AF confers upon the hospital system by way of hospital admissions and readmissions. Chapter 5 identifies the predictors of hospital admission for AF patients presenting via the emergency department and moreover determines if all admissions are medically warranted. This study ascertained that AF patients presenting with congestive heart failure and a concurrent infection were significantly likely to be admitted to hospital for treatment and a significant proportion of patients who were admitted were low-risk AF and admission was not medically justified. This highlights a need for new management strategies in order to prevent unnecessary hospital admissions.

Lastly, chapter 6 examines the factors that increase the likelihood of readmission to hospital among AF patients. The findings showed that a substantial number of patients with index presentation for AF were readmitted to hospital. Patients who were younger and discharged on rhythm control medications were more likely to burden the hospital system with frequent AF readmissions. This study stressed the need for specialised outpatient clinics and educational interventions that could potentially reduce the increasing numbers of AF patients re-presenting to hospital.

Declaration

I certify that this work contains no material, which has been accepted for the award of any other degree or diploma in any university or other tertiary institution. To the best of my knowledge and belief, it contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the explicit permission of the University of Adelaide and if applicable, any other partner institution.

I give consent to this copy of my thesis, when deposited in the University of Adelaide Library, being made available for loan and photocopying, subject to the Copyright Act of 1968.

Additionally, I give permission for the digital version of my thesis to be available on the web, via the University's digital search repository, the Australian Digital Thesis Program (ADTP), the Library catalogue and through web search engines, unless permission has been granted by the University to restrict access for a certain period of time.

Geetanjali Rangnekar

August 2014

Acknowledgements

I would like to thank Professor Prashanthan Sanders, my primary supervisor, for his guidance and support during my doctoral degree. His enthusiasm and constant innovation has been and continues to be inspirational. I would also like to thank my co-supervisor Dr Kurt-Roberts Thomson for his help and encouragement during my studies. Special thanks to my co-supervisors, Dr. Anthony Brooks for guidance provided during the study design and execution phase and for assistance with SPSS; Dr. Scott Willoughby for assistance with the new AF studies and to Dr. Dennis Lau for his patience, assistance and guidance during thesis preparation.

I would like to thank the cardiology fellows at the Centre for Heart Rhythm Disorders for their feedback and encouragement. I have enjoyed and will cherish my time working alongside my fellow PhD candidates at the Centre for Heart Rhythm Disorders: Carlee Schultz, Melissa Neo, Wei Wen Lim. In particular, thank-you to Carlee Schultz for her help during the new AF studies. I would also like to acknowledge the staff at the Cardiovascular Centre, past and present, who helped and accommodated me during the conduction of my PhD studies; Michelle Sanders, Melissa Middledorp, Aimie Paukner, Rebecca Leinonen, Sharon King, Elena Pancewicz, Lorraine Lee, Emily Rasheed and Julia Kim.

Last but not least, I would like to say a huge thank you to my amazing family; parents, sister, brother in law, aunt, uncle, and cousins; without whose unwavering understanding, encouragement and love this PhD would have not been possible. Thank you to my wonderful friends for their unstinting fortitude, humour and love which got me through some of the most trying times.

Communications to Learned Societies

Chapter Two

1. Presentation: Presented at The Australian Society for Medical Research South Australian Annual Scientific Meeting, May 2014, Adelaide, Australia.

Chapter Three

1. Presentation: Presented at the 59th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2011, Perth, Australia and published in abstract form (Heart, Lung and Circulation 2011, 20:S105).
2. Presentation: Presented at the Heart Rhythm Society 33rd Annual Scientific Sessions, May 2012, Boston, United States of America and published in abstract form (Heart Rhythm 2012, 9:5, S7).
3. Presentation: Presented at the 60th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2012, Brisbane, Australia and published in abstract form (Heart, Lung and Circulation 2012, 21:S104-5).
4. Presentation: Presented at the 5th Asia-Pacific Heart Rhythm, Society Scientific Sessions, October 2012, Taipei, Taiwan and published in abstract form (APHRS Conference Proceedings 2012).
5. Presentation: Presented at the Heart Rhythm Society 34th Annual Scientific Sessions, May 2013, Denver, United States of America and published in abstract form (Heart Rhythm 2013, 10:5, S218).
6. Presentation: Presented at Heart Foundation National Conference, May 2013, Adelaide, Australia.

7. Presentation: Presented at the 61st Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2013, Gold Coast, Australia and published in abstract form (Heart, Lung and Circulation 2013, 22:S102).

Chapter Four

1. Presentation: Presented at the Heart Rhythm Society 34th Annual Scientific Sessions, May 2013, Denver, United States of America and published in abstract form (Heart Rhythm 2013, 10:5, S1).
2. Presentation: Presented at Heart Foundation National Conference, May 2013, Adelaide, Australia.
3. Presentation: Presented at the 61st Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2013, Gold Coast, Australia and published in abstract form (Heart, Lung and Circulation 2013, 22:S97-98).
4. Presentation: Presented at the Heart Rhythm Society 35th Annual Scientific Sessions, May 2014, San Francisco, United States of America and published in abstract form (Heart Rhythm 2014, 11:5, S106).

Chapter Five

1. Presentation: Presented at The Australian Society for Medical Research South Australian Annual Scientific Meeting, May 2014, Adelaide, Australia.

Chapter Six

1. Presentation: Presented at the Heart Rhythm Society 33rd Annual Scientific Sessions, May 2012, Boston, United States of America and published in abstract form (Heart Rhythm 2012, 9:5, S383).

2. Presentation: Presented at the 60th Cardiac Society of Australia and New Zealand the Scientific Meeting, August 2012, Brisbane, Australia and published in abstract form (Heart, Lung and Circulation 2013, 21:S107-8).
3. Presentation: Presented at the School of Medicine Postgraduate Research Conference, August 2012, Adelaide, Australia.
4. Presentation: Presented at the 5th Asia-Pacific Heart Rhythm, Society Scientific Sessions, October 2012, Taipei, Taiwan and published in abstract form (APHRs Conference Proceedings 2012).

Prizes and Awards During Candidature

1. Best poster presentation (PhD) Award, Australian Society for Medical Research (ASMR), South Australian Scientific Meeting, 2014.
2. Best Poster Prize, The University of Adelaide, Faculty of Health Sciences, Department of Medicine, Postgraduate Research Conference, 2012.
3. Finalist, Best poster prize, Heart Foundation National Conference, 2013.